The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...
Zacks Investment Research on MSN
Merck indicates better growth visibility in post-Keytruda LOE period
Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...
A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...
The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...
Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results